TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nucana ( (NCNA) ) has provided an update.
On November 13, 2025, NuCana plc announced its financial results for the third quarter of 2025. The company reported a significant reduction in operating losses compared to the previous year, with a loss of £779,000 for the quarter, down from £5.3 million in the same period in 2024. Despite the improvement, NuCana continues to face financial challenges, with a total comprehensive loss of £267,000 for the quarter. Additionally, the company announced the resignation of Dr. Bali Muralidhar from its Board of Directors, effective October 21, 2025, noting that the resignation was not due to any disagreements with the company.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Underperform.
Nucana’s overall score is primarily impacted by its financial instability and negative valuation metrics. The significant lack of revenue generation and operational losses are major concerns. Despite showing strong cash management and low leverage, the company’s technical indicators suggest a bearish trend, further weighing down the score. The poor valuation metrics, such as a negative P/E ratio, are offset by potential speculative interest due to the low stock price. The absence of notable earnings call insights or corporate events means these factors did not influence the score.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a biotechnology company based in the United Kingdom, specializing in the development of novel cancer treatments. The company focuses on transforming chemotherapy by developing a new class of medicines known as ProTides, which aim to improve the efficacy and safety of existing cancer therapies.
Average Trading Volume: 444,515
Technical Sentiment Signal: Sell
Current Market Cap: $7.23M
See more insights into NCNA stock on TipRanks’ Stock Analysis page.